SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
... may include stiffness and tenderness of the
joints and surrounding tissue and reduced range of motion.
joints of the hands, wrists, knees, ankles, feet, lower ... the spine, can affect internal organs, peripheral
joints and vision.
About SIMPONI
SIMPONI is a ...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
... Patients with at least 3 swollen and tender
joints and active psoriatic skin lesions of at least two ... may include stiffness and tenderness of the
joints and surrounding tissue and reduced range of motion.
joints of the hands, wrists, knees, ankles, feet, lower ...
Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
... process, relieves both inflammation of the
joints and certain systemic effects of RA. The extensive ... IL-6
IL-6 is a common protein found in all
joints in the body and is a natural substance that can ... swelling, pain and movement limitation around
joints of the hands, feet, elbows, knees and neck that ...
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
... inhibit the progression of structural damage to
joints in patients with rheumatoid arthritis (RA). The ... process, relieves both inflammation of the
joints and certain systemic effects of RA. The extensive ... IL-6
IL-6 is a common protein found in all
joints in the body and is a natural substance that can ...
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
... process, relieves both inflammation of the
joints and certain systemic effects of RA. The ... IL-6
IL-6 is a common protein found in all
joints in the body and is a natural substance that can ... swelling, pain and movement limitation around
joints of the hands, feet, elbows, knees and neck that ...
New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
... process, relieves both inflammation
of the
joints and certain systemic effects of RA. The extensive ... IL-6
IL-6 is a common protein found in all
joints in the body and is a
natural substance that can ... pain and movement limitation around
joints of the hands, feet,
elbows, knees and neck that ...
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
... process, relieves both inflammation of the
joints and
certain systemic effects of RA. The extensive ... IL-6
IL-6 is a common protein found in all
joints in the body and is a
natural substance that can ... pain and movement limitation around
joints of the hands, feet,
elbows, knees and neck that ...
Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
... Pain, Symptoms; May Now Have Lasting Effect on
joints Following Cessation ... this study
suggest that Pycnogenol may help the
joints to recover.
With osteoarthritis cases on the ... mechanisms of
Pycnogenol has allowed the
joints to recover."
In another study this year (also ...
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
... process, may
reduce inflammation of the
joints and relieve certain systemic effects of
RA. The ... IL-6
IL-6 is a common protein found in all
joints in the body and is a
natural substance that can ... pain and movement limitation around
joints of the hands, feet,
elbows, knees and neck that ...
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
... in the
double-blind portion of the study. The
joints were stratified 2:1
Metacarpal Phalangeal Joint, ... met with 64% (130 of 203) of patients'
primary
joints treated with XIAFLEX achieving = 5 degrees of ... met, with 44.4% (20
of 45) of patients' primary
joints treated with XIAFLEX achieving = 5
degrees of ...
New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
... treatment by measuring
structural damage in the
joints through X-rays; disease activity was
measured ... process, may
reduce inflammation of the
joints and relieve certain systemic effects of
RA. The ... IL-6
IL-6 is a common protein found in all
joints in the body and is a
natural substance that can ...
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
... process, may
reduce inflammation of the
joints and relieve certain systemic effects of
RA. The ... IL-6
IL-6 is a common protein found in all
joints in the body and is a
natural substance that can ... pain and movement limitation around
joints of the hands, feet,
elbows, knees and neck that ...
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
... 28
(DAS28), which measures tender and swollen
joints and overall disease
activity including ... with at least three swollen and tender
joints and active psoriatic
skin lesions of at least 2 ... may include
stiffness and tenderness of the
joints and surrounding tissue and reduced
range of ...
Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
... (MP) or proximal interphalangeal (PIP)
joints to within
0 to 5 degrees of normal. Upon ... than 50 years.(1) The most frequently affected
joints associated with Dupuytren's
contracture are the
joints called the metacarpophalangeal joint, or ...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
... population, patients who failed biologic therapies, their bones and
joints appear to respond to R788, but the objective and subjective components of ... system into overdrive where it ultimately causes inflammation in the
joints and destroys soft tissues, cartilage and bone. Rigel's R788 is a novel, ...
Texas Back Institute Leads Way in New Facet Joint Clinical Trial
... lower back and leg pain. Specifically, TFAS replaces the
degenerated facet
joints with an implant that is affixed to the affected
vertebrae and designed to restore the natural motion of the surgically
removed facet
joints and spinal ligaments.
About Texas Back Institute
Texas Back Institute, ...
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
... nevertheless showed a slowed progression of
structural damage within the
joints as measured at Week 16 by analysis of
radiographic data.
Additional data ... joint damage and deformity and maintaining function of the
affected
joints to prevent disability.
Traditional treatments for RA include ...
FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
... that the administration of Kogenate FS to
prevent bleeding into the
joints was more beneficial to joint health and
function than 'on-demand' ... prophylaxis group were eight times more likely to have damage-free
joints than those from the episodic group. -- The prophylaxis group had an 81.5 ...
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
... inflamed joints) have been shown to be
present in synovial fluid from the
joints of RA patients. By blocking the
CCR1 ligands including the super-activated ... the recruitment of immune
cells, both innate and adaptive, into affected
joints plays a key role in
the inflammatory process and the ensuing joint ...
First Human Implant of New Archus Orthopedics Facet Replacement System
... spinal stenosis, a condition in which degenerative changes in
the facet
joints result in compression of spinal nerves producing
neurological symptoms in ... accompanied by spinal fusion. Archus products replace degenerative
facet
joints with a prosthetic joint implant intended to restore stability
and normal ...
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
... used to define flare, and worsening in
greater than or equal to two
joints was necessary if the number of active
joints or
joints with limitation of motion was used as one of the three JIA
core set ...
MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
... levels of GM-CSF and its receptor have been found in the
joints of
patients with RA. This provides a strong rationale for the potential ... mortality. The disease is
characterized by inflammation of the synovial
joints that can result in
pain, swelling and joint damage with secondary ...
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
... involved in the inflammatory process, may reduce inflammation of
the
joints and relieve certain systemic effects of RA.
The BLA submission to the ... of RA include redness,
swelling, pain and movement limitation around
joints of the hands, feet,
elbows, knees and neck that leads to loss of function. ...
Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
... of RA include redness,
swelling, pain and movement limitation around
joints of the hands, feet,
elbows, knees and neck that leads to loss of function. ... in patients with RA. It combines information from
28 tender and swollen
joints (range0-28), erythrocyte sedimentation rate,
and a general health ...
Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
... for use in patients with inflammatory
arthritis who have one or more
joints that do not fully respond to systemic
protein therapy. The product ... activity of TNF-alpha. Direct injection of tgAAC94
into affected
joints leads to the localized production of secreted TNFR:Fc
within joint cells, ...
Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results
... the body's immune system forms antibodies that can attack virtually any healthy organ or tissue, from the kidneys to the brain, heart, lungs, skin,
joints and blood. No new treatments for lupus have been approved in almost 50 years and many currently used treatments are as toxic as the disease itself. ...
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
... for an extended period of time; and VOLTAREN(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of
joints amenable to topical treatment such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by Novartis AG; SANCTURA(R) and its XR ...
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
... in the U.S. It is a chronic inflammatory disease that puts the body's immune system into overdrive where it ultimately causes inflammation in the
joints and destroys soft tissues, cartilage and bone. Rigel's R788 is a novel, orally available syk kinase inhibitor designed to interrupt the cellular ...
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
... and neutralizes excess TNF-alpha, a protein that when overproduced in the body, due to chronic inflammatory diseases, can cause inflammation in the
joints of people with rheumatoid arthritis. The first once-monthly subcutaneous anti-TNF-alpha therapy, SIMPONI is approved in Canada and the United States ...
The Injured Obese Child: Let's Give Him Some Ankle Support
... time. "Though it is not well studied, we suspect that increased force due to increased weight puts undue strain on the ligaments, tendons, muscles,
joints and bones of these particular children. Repetitive forces with increased weight likely results in more damage to their bodies and lengthy recovery ...
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
... for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of
joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, ...
Applying Clinical Findings to the Practice of Medicine
... Dr. Hurst and his team injected Clostridial collagenase to the joint and reduced contractures in metacarpophalangeal and proximal interphalangeal
joints within zero degrees to five degrees of normal extension after the last injection.
An additional study in humans with frozen shoulder yielded ...
Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
... for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of
joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, ...
Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults
... heavy cannabis use during adolescence. On average, they had smoked marijuana from age 13 till age 18 or 19, and reported smoking nearly 6 marijuana
joints daily in the final year before they stopped using the drug.
The study team performed a type of magnetic resonance imaging scan called diffusion ...
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
... for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of
joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, ...
Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
... injection with EUFLEXXA(R). The safety and effectiveness of injecting
EUFLEXXA(R) into the knee together with other injectable medications or
into
joints other than the knee have not been studied. The safety and
effectiveness of treatment cycles of fewer than 3 injections or of repeated
treatment ...
Building a New and Better Ankle
... and causing pain
Total ankle replacements can offer patients:
-- Better motion of the ankle compared to fusion -- Protection in the small
joints below and in front of the ankle from developing arthritis -- Relief of ankle pain Currently, there are about 20 total ankle replacement ...
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
... acid in the blood stream. These
abnormally elevated levels lead to the deposition of uric acid crystals in
and around the connective tissue of the
joints and in the kidneys, leading
to inflammation, the formation of disfiguring nodules (tophi), intermittent
attacks of severe pain (acute flares), and ...
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
... at the Annual European
Congress of Rheumatology (EULAR).
The Phase 1/2 study evaluated multiple doses of tgAAC94 administered
directly to affected
joints with or without concurrent systemic TNF
antagonist therapies. The study achieved its primary endpoint of safety and
tolerability.
"We are ...
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
... double-blind, placebo controlled
study included 637 MTX-naive adults with RA. Patients with active RA who
had more than four tender and swollen
joints were included in the
multicenter study. Adult patients were randomly assigned into four groups
to receive placebo every four weeks plus MTX 20 mg per ...